Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01486433 · ClinicalTrials.gov registry record · Phase 1
The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects
A Phase 1 study of Hypertriglyceridemia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT01486433 is a Phase 1 study of Hypertriglyceridemia that has completed, run by AstraZeneca. The registered enrollment target is 52 participants, below the 174-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01486433, a Phase 1 study of Hypertriglyceridemia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to determine the effect of multiple doses of Epanova® (omega fatty acids) on the pharmacokinetics (PK) of multiple 40 mg doses of simvastatin.
Conditions Studied
Interventions
- DRUG Simvastatin
- DRUG omefas
- DRUG acetylsalicylic acid (ASA)
Study Locations (1)
Arizona
- - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01486433
The ClinicalTrials.gov registry entry for NCT01486433 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 174-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (70% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertriglyceridemia appearing as the primary indexed condition, and to 3 interventions - of which Simvastatin is the first listed.
NCT01486433 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT01486433 about?
NCT01486433 is a clinical study titled "The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects". The primary objective is to determine the effect of multiple doses of Epanova® (omega fatty acids) on the pharmacokinetics (PK) of multiple 40 mg doses of simvastatin.
What is the current status of trial NCT01486433?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2011-11. Estimated completion is 2012-03.
What conditions does trial NCT01486433 study?
This clinical trial studies the following conditions: Hypertriglyceridemia.
What interventions are being tested in trial NCT01486433?
The interventions under investigation include: Simvastatin (DRUG), omefas (DRUG), acetylsalicylic acid (ASA) (DRUG).
Who is sponsoring clinical trial NCT01486433?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01486433 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
ACTIVE NOT RECRUITING · Phase 1
-
Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)
COMPLETED · Phase 1
-
Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals
COMPLETED · Phase 1
-
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
COMPLETED · Phase 1
-
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
COMPLETED · Phase 1
-
Study of Gemcabene in Adults With FPLD
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.